Scott Wolchko | President and CEO |
Chris Storgard | Chief Medical Officer |
Dan Shoemaker | Chief Scientific Officer |
Edward Tenthoff | Piper Jaffray |
David Nierengarten | Wedbush Securities |
Do Kim | BMO Capital Markets |
Welcome to Fate Therapeutics First Quarter 2018 Financial Results Conference Call. At this time all participants are in a listen-only mode. This call is being webcast live on the Investors & Media section of Fate webcast at fatetherapeutics.com.
As a reminder, today’s call is being recorded. I would now like to introduce Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.